FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development10 Sep 2019
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.
FUJIFILM Irvine Scientific has introduced BalanCD Gal Supplement. The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.
Glycosylation is a critical aspect in development and optimization of protein-based therapeutics. The type and level of glycosylation can significantly affect antibody binding, function, and therapeutic efficacy. Galactosylation (the glycosylation of galactose) is a key method for controlling product quality due to the significant impact it has on antibody function, and the ability to control levels of galactosylation through the cell culture medium.
BalanCD Gal Supplement is a chemically defined, animal component-free formula designed to increase N-linked galactosylation with a scalable protocol, offering researchers a simple method to control the process through the cell culture medium. The supplement is effective at low concentrations and is compatible with any basal growth medium.
BalanCD Gal Supplement has been developed as part of the BalanCD CHO media platform - an extended portfolio of chemically defined, animal component-free growth and feed media formulated using Rational Culture Media Design. This multidimensional approach uses sequential, complementary development methods to leverage FUJIFILM Irvine Scientific scientists’ expertise in the effects of components and process parameters. The result is a media platform that delivers the precise combination of nutrients to maximize productivity, growth, and viability of CHO cell lines.
“The BalanCD Gal Supplement has been designed to incorporate seamlessly into our BalanCD media portfolio, providing researchers in biotherapeutic development with a holistic, efficient growth and production platform. Developed by our expert research and development group, the new supplement supports scientists in streamlining workflows, ultimately to advance emerging therapies,” said Robert Newman PhD, Chief Scientific Officer, FUJIFILM Irvine Scientific.
Study demonstrates potential of blood test for early lung cancer detection
16 Sep 2019
Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer.Read more
M2i Life Sciences completes a historic fundraising of 60 million Euros
16 Sep 2019
To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).Read more
BioCity backs world's first Rx to OTC switch incubator
5 Sep 2019
Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.Read more
Dutch company receives €20 million for skin cancer diagnostic test
3 Sep 2019
The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.Read more
AbbVie axes Rovalpituzumab Tesirine R&D program
2 Sep 2019
Independent Data Monitoring Committee recommended terminating the study due to lack of survival benefit.Read more
Improving anxiety-induced insomnia with lavender oil
29 Aug 2019
New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.Read more
Grant from Innovate UK to fund gel stabilisation technologies development
28 Aug 2019
Atelerix Consortium awarded £267,000 Innovate UK Grant for collaboration with the Cell and Gene Therapy Catapult and Rexgenero on cell therapy stabilisation technologies.Read more
Exciting new vaccine targets killer disease TB
28 Aug 2019
Australian researchers produce early-stage vaccine which is inhaled into the lungs.Read more
Rapid adoption of Carterra’s LSA instrument drives European expansion
20 Aug 2019
Company's antibody screening platform minimizes the risk of missing a blockbuster.Read more
IDT launches oPools Oligo Pools
19 Aug 2019
The longest, highest fidelity, and ready-to-use custom oligo pools on the market.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation